About brexucabtagene autoleucel
CD19-directed CAR T-cell immunotherapy
Used for
- Treatment of adults with relapsed or refractory mantle cell lymphoma.
- Treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
Usual adult dose
One patient-specific intravenous infusion; dose depends on body weight and indication, following lymphodepleting chemotherapy.
Common side effects
- Cytokine release syndrome
- Neurologic toxicity, including confusion or seizures
- Infections and low blood-cell counts
- Fever, fatigue, and nausea
Important warnings
- Can cause life-threatening cytokine release syndrome and neurologic toxicity.
- Treatment requires specialist monitoring at a certified center.
- May cause severe or prolonged low blood-cell counts and infections.
- Avoid driving until neurologic effects have resolved.
Pregnancy
May cause fetal harm; pregnancy status is assessed before treatment. Effects on fertility are possible.
Breastfeeding
Breastfeeding is not recommended during treatment; safety is unknown.
Interactions
- Lymphodepleting chemotherapy is given before infusion.
- Avoid live vaccines around treatment; vaccine safety may be affected.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.